Gen QA

MEMBER LOGIN

MENU menu

Close close menu

Sarcoma

BACK TO EQA DIRECTORY

Testing for the detection of recurrent abnormalities associated with sarcomas in FFPE.

EQA INFORMATION

EQA Code
TSA
Submission
Clinical Report
Techniques
Any methodology
Eligibility
All laboratories worldwide
Language
English, French, German, Italian, Polish, Portuguese, Spanish
EQA Accreditation
EQA accredited to ISO 17043:2023
EQA open

20 October 2025

Testing period
6 weeks

OTHER INFORMATION

What are participants required to do?
  • Enrolled participants will receive details by email when an EQA is open for assessment and/or samples have been dispatched.  
  • Participants are expected to access the instructions and information for the cases/samples online and to analyse them according to their laboratory/centre protocols. 
  • Participants must submit their anonymised results by the deadline using their standard laboratory report or a proforma provided by GenQA.  The submitted results are independently assessed for the accuracy of the analytical/genotyping results, clinical interpretation of the results (if appropriate) and clerical accuracy (including report layout and content). 

What can I expect as a participant?
Every participant will receive:
  • An Individual Laboratory/Centre Report (ILR/ICR) with educational advice for each distribution of this EQA.
  • The Summary report for each distribution of this EQA which contains information regarding general findings, a summary of methodologies used, common errors, number of participants and benchmarking. 
  • Access to a live Performance Certificate summarising your performance status for all EQAs in which you are enrolled.

Please note: EQA details may be subject to change prior to EQA distribution.  
 

PRODUCTS

Sample type: FFPE (Formalin Fixed Paraffin Embedded sections)
Testing/analysis: EWSR1, DDIT3, SS18, MDM2, JAZF1, USP6, FUS, NR4A3, TFE3, FOXO1.  
 

Two cases will be "more frequent" alterations in sarcoma e.g. EWSR1, SS18, USP6, DDIT3, FOXO1, FUS  rearrangements or MDM2 amplification with the third case sometimes being a "less frequent" rearrangement or SNV change.
Conditions/Gene target(s):
  • Sarcoma
  • Ewings sarcoma
  • synovial sarcoma
  • well differentiated liposarcoma/de-differentiated liposarcomas
  • myxoid liposarcoma
  • alveolar rhabdomyosarcoma
  • endometrial stromal tumours
  • nodular fascitis
  • aneurysmal bone cysts
  • low-grade fibromyxoid sarcomas
  • sclerosing epitheliod sarcomas
  • extra-skeletal chondrosarcomas
  • clear cell sarcomas
  • desmoplastic small round cell tumour
  • alveolar soft part sarcoma
We aim to include a variety of tests within each EQA.  For this EQA you may opt out of any case if it is outside of your routine laboratory scope, by following the instructions in the EQA Distribution letter. 
Number of cases: Three

PURCHASE NOW

 

ASK A QUESTION

Sarcoma

Enter your details here: